Allos Therapeutics — Merger or Acquisition (July 2011)
15 slides from Allos Therapeutics's merger presentation, Jul 20, 2011
Slide 1: AMAG Pharmaceuticals and Allos Therapeutics to Merge
I N V E S T O R P R E S E N T A T I O N AMAG Pharmaceuticals and Allos Therapeutics to Merge p g July 20, 2011 Creates Company With Strengthened Commercial Portfolio 1
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “esti
Slide 3: Important Merger Information and Where to Find It
Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed merger between AMAG and Allos will be submitted to the re
Slide 4: Merger Highlights
Merger Highlights 4 Terms • Stock for stock transaction • 0 1282 AMAG shares for each Allos Allos stockholders will receive 0.1282 share held; total equity value of approximately $686 million Ownership at Closing • AMAG 61% / Allos 39% Cash Position • 30 373 7M; June 30, 2011 combined cash and inves
Slide 5: Financial and Strategic Benefits of Merger
Financial and Strategic Benefits of Merger . Combined company will have a diversified portfolio of commercial products 5 focused on high-potential markets with overlapping customer segments . FERAHEME® (ferumoxytol injection) – for the treatment of iron deficiency anemia (IDA) in adult patients with
Slide 6: Two Commercial Products with Compelling Value
Two Commercial Products with Compelling Value FERAHEME FOLOTYN Description . Therapeutic iron formulation delivered via intravenous (IV) injection . U S l J . Folate analogue metabolic inhibitor delivered via intravenous (IV) injection . U S l S t b Propositions 6 U.S. approval June 2009 U.S. approv
Slide 7: FERAHEME and FOLOTYN Have Attractive Opportunities for Continued Growth
FERAHEME and FOLOTYN Have Attractive Opportunities for Continued Growth and Value Creation, Sharing Many Common Call Points Market detail Non-dialysis CKD Incidence 7 . The overall U.S. non-dialysis IV iron market is estimated to be $400 million . 1.6 million Americans are estimated to have non-dial
Slide 8: Strengthened Commercial Company Expected to Leverage Customer Relationships
Strengthened Commercial Company Expected to Leverage Customer Relationships for Brands . Products: FERAHEME and FOLOTYN 8 . Address attractive markets with targeted sales force . Improved share of voice . Target call points include hematology / oncology infusion centers, g p gy/ gy , community clini
Slide 9: Global Development Programs Expected to Drive Expanded Market Opportunities
Global Development Programs Expected to Drive Expanded Market Opportunities . Strategic collaborations outside the U.S. with industry leaders — with T k d i l U S i d 3Sbi i Chi f FERAHEME d 9 Takeda in several ex-U.S. regions and 3Sbio in China for FERAHEME, and Mundipharma for FOLOTYN ex-U.S. and
Slide 10: Multiple Milestones Provide Future Growth Opportunities
Multiple Milestones Provide Future Growth Opportunities 2H 2011 Mil t 2012 Mil t 10 . CHMP recommendation expected for EU MAA for IDA in CKD D i i t d di C di . sNDA submission to FDA and EMA for broad IDA indication Milestones Milestones EME ME . Decision expected regarding Canadian regulatory appl
Slide 11: Potential for Significant Milestone Payments and Royalties from Established Collaborations
Potential for Significant Milestone Payments and Royalties from Established Collaborations FERAHEME FOLOTYN 11 . Takeda: Strategic alliance for developments and commercialization of FERAHEME . $60 million upfront payment received in 2010 . Up to $220 million in potential development and milestones $
Slide 12: Combined Company Expected to Realize Annual Synergies of $55 to $60 Million
Combined Company Expected to Realize Annual Synergies of $55 to $60 Million Expected Annual Primary Driver 12 Synergies Selling, General and Administrative $38 mm - $41 mm .Rationalization of redundant public company expenses (includes facilities rationalization) . Rationalization of redundant perso
Slide 13: 2010 Net Product Revenues
2010 Net Product Revenues 2010 Net Product Revenue ($MM) 2010 Net Product Revenue Contribution % 13 FOLOTYN 90 100 60 70 80 30 40 50 FERAHEME 0 10 20 FERAHEME FOLOTYN Combined
Slide 14: Financial and Strategic Benefits of Merger
Financial and Strategic Benefits of Merger . Combined company will have a diversified portfolio of commercial d f d hi h i l k i h l i 14 products focused on high-potential markets with overlapping customer segments . FERAHEME® (ferumoxytol injection) – for the treatment of iron deficiency anemia (I
Slide 15: AMAG Pharmaceuticals and Allos Therapeutics to Merge
I N V E S T O R P R E S E N T A T I O N AMAG Pharmaceuticals and Allos Therapeutics to Merge p g July 20, 2011 Creates Company With Strengthened Commercial Portfolio
Allos Therapeutics — Merger or Acquisition (July 2011) on 6ix